Latest From Epizyme Inc.
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Epizyme Inc.
- Senior Management
Robert Bazemore, Pres. & CEO
Paolo Tombesi , CFO
Shefali Agarwal, CMO
Matthew Ros, Chief Strategy & Business Officer
- Contact Info
Phone: (617) 229-5872
400 Technology Sq., 4th Fl.
Cambridge, MA 02139